(Reuters) – Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government has granted the drugmaker a $450 million contract to make and supply its double antibody cocktail that is being tested against COVID-19.
The antiviral cocktail, REGN-COV2, is in separate clinical trials both for treating and preventing COVID-19, the company said https://reut.rs/2O2ADgu.
The funding comes under the U.S. government’s “Operation Warp Speed” program.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
